IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...
Barclays lowered the firm’s price target on Iqvia (IQV) to $235 from $255 and keeps an Overweight rating on the shares. The firm says the life ...
Over the past year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a significant stake in the company which ...
While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...
(HealthDay News) — Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in October ...
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, ...
BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...